Azelon receives $4.5M to advance nasal spray teriparatide for osteoporosis
This article was originally published in Scrip
Executive Summary
Azelon Pharmaceuticals, formerly Zelos Therapeutics, has secured $4.5 million Series A financing led by Prospect Venture Partners to support the development of the company's ZT-034, a nasal spray formulation of the parathyroid hormone analog teriparatide for the treatment of osteoporosis.